Study on the blood-borne virus co-infection and T lymphocyte subset among intravenous drug users

Table 4 CD percentages and cytokine level in IDU with HIV and HBV co-infection (mean ± SD)

Group	n	CD3 (%)	CD4 (%)	CD8 (%)	CD4/CD8	IFN-γ(ng/L)	IL-4 (ng/L)
Negative1	40	56.80 ± 4.42	41.90 ± 4.16	29.08 ± 2.85	1.44 ± 0.13	288.01 ± 40.03	20.76 ± 1.87
HBV infection	29	58.85 ± 4.13	41.57 ± 4.21	29.16 ± 2.65	1.43 ± 0.14	289.82 ± 42.56	20.94 ± 1.33
HIV infection	27	54.27 ± 4.23b	39.49 ± 3.47a	28.98 ± 3.11	1.36 ± 0.15b	265.43 ± 38.71a	20.23 ± 1.34
HIV+HBV-DNA-	30	53.95 ± 3.77b	39.36 ± 2.86b	28.91 ± 2.35	1.36 ± 0.13b	263.57 ± 43.65a	20.84 ± 1.56
HIV+HBV-DNA+	15	53.68 ± 4.41a	39.22 ± 3.53a	28.67 ± 3.14	1.37 ± 0.15b	262.83 ± 38.74a	20.61 ± 1.49

^aP < 0.05,

^bP < 0.01 vs negative cases.

¹Viral infection markers were not discovered in IDU.